Literature DB >> 26901705

Hematopoietic stem cell transplantation for adults with EBV-positive T- or NK-cell lymphoproliferative disorders: efficacy and predictive markers.

A Arai1, C Sakashita1, C Hirose2, K-I Imadome3, M Yamamoto1, M Jinta1, S Fujiwara4, M Tomita5, N Shimizu6, T Morio7, O Miura1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26901705     DOI： 10.1038/bmt.2016.3

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

Review 1.  Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency?

Authors:  Hiroshi Kimura
Journal:  Rev Med Virol       Date:  2006 Jul-Aug       Impact factor: 6.989

2.  High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.

Authors:  M Hoegh-Petersen; D Goodyear; M N Geddes; S Liu; A Ugarte-Torres; Y Liu; J T Walker; K Fonseca; A Daly; P Duggan; D Stewart; J A Russell; J Storek
Journal:  Bone Marrow Transplant       Date:  2010-11-08       Impact factor: 5.483

Review 3.  Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection.

Authors:  Motohiko Okano; Keisei Kawa; Hiroshi Kimura; Akihiro Yachie; Hiroshi Wakiguchi; Akihiko Maeda; Shosuke Imai; Shouichi Ohga; Hirokazu Kanegane; Shigeru Tsuchiya; Tomohiro Morio; Masaaki Mori; Shumpei Yokota; Shinsaku Imashuku
Journal:  Am J Hematol       Date:  2005-09       Impact factor: 10.047

4.  Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction.

Authors:  H J Wagner; M Wessel; W Jabs; F Smets; L Fischer; G Offner; P Bucsky
Journal:  Transplantation       Date:  2001-09-27       Impact factor: 4.939

5.  Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection.

Authors:  K Kawa; A Sawada; M Sato; T Okamura; N Sakata; O Kondo; T Kimoto; K Yamada; S Tokimasa; M Yasui; M Inoue
Journal:  Bone Marrow Transplant       Date:  2010-05-24       Impact factor: 5.483

6.  EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases.

Authors:  Hiroshi Kimura; Yoshinori Ito; Shinji Kawabe; Kensei Gotoh; Yoshiyuki Takahashi; Seiji Kojima; Tomoki Naoe; Shinichi Esaki; Atsushi Kikuta; Akihisa Sawada; Keisei Kawa; Koichi Ohshima; Shigeo Nakamura
Journal:  Blood       Date:  2011-11-16       Impact factor: 22.113

7.  Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Authors:  Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

8.  Sequential monitoring of serum IL-6, TNF-α, and IFN-γ levels in a CAEBV patient treated by plasma exchange and immunochemotherapy.

Authors:  Ayako Arai; Ayako Nogami; Ken-Ichi Imadome; Morito Kurata; Naomi Murakami; Shigeyoshi Fujiwara; Osamu Miura
Journal:  Int J Hematol       Date:  2012-09-16       Impact factor: 2.490

9.  T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections.

Authors:  J F Jones; S Shurin; C Abramowsky; R R Tubbs; C G Sciotto; R Wahl; J Sands; D Gottman; B Z Katz; J Sklar
Journal:  N Engl J Med       Date:  1988-03-24       Impact factor: 91.245

Review 10.  Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD.

Authors:  Koichi Ohshima; Hiroshi Kimura; Tadashi Yoshino; Chul Woo Kim; Young H Ko; Seung-Suk Lee; Suat-Cheng Peh; John K C Chan
Journal:  Pathol Int       Date:  2008-04       Impact factor: 2.534
  10 in total
  7 in total

1.  Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification.

Authors:  Ichiro Yonese; Chizuko Sakashita; Ken-Ichi Imadome; Tohru Kobayashi; Masahide Yamamoto; Akihisa Sawada; Yoshinori Ito; Noriko Fukuhara; Asao Hirose; Yusuke Takeda; Masanori Makita; Tomoyuki Endo; Shun-Ichi Kimura; Masataka Ishimura; Osamu Miura; Shouichi Ohga; Hiroshi Kimura; Shigeyoshi Fujiwara; Ayako Arai
Journal:  Blood Adv       Date:  2020-07-14

Review 2.  How we treat chronic active Epstein-Barr virus infection.

Authors:  Akihisa Sawada; Masami Inoue; Keisei Kawa
Journal:  Int J Hematol       Date:  2017-02-16       Impact factor: 2.490

3.  Antineoplastic and anti-inflammatory effects of bortezomib on systemic chronic active EBV infection.

Authors:  Mayumi Yoshimori; Haruna Shibayama; Ken-Ichi Imadome; Fuyuko Kawano; Ayaka Ohashi; Miwako Nishio; Norio Shimizu; Morito Kurata; Shigeyoshi Fujiwara; Ayako Arai
Journal:  Blood Adv       Date:  2021-04-13

Review 4.  Treatment Advances in EBV Related Lymphoproliferative Diseases.

Authors:  Kebing Lv; Ting Yin; Min Yu; Zhiwei Chen; Yulan Zhou; Fei Li
Journal:  Front Oncol       Date:  2022-04-19       Impact factor: 5.738

Review 5.  Hematopoietic Stem Cell Transplantation for the Treatment of Epstein-Barr Virus-Associated T- or NK-Cell Lymphoproliferative Diseases and Associated Disorders.

Authors:  Akihisa Sawada; Masami Inoue
Journal:  Front Pediatr       Date:  2018-11-06       Impact factor: 3.418

6.  STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target.

Authors:  Erika Onozawa; Haruna Shibayama; Honami Takada; Ken-Ichi Imadome; Sho Aoki; Mayumi Yoshimori; Norio Shimizu; Shigeyoshi Fujiwara; Takatoshi Koyama; Osamu Miura; Ayako Arai
Journal:  Oncotarget       Date:  2018-07-24

Review 7.  Chronic Active Epstein-Barr Virus Infection: The Elucidation of the Pathophysiology and the Development of Therapeutic Methods.

Authors:  Ayako Arai
Journal:  Microorganisms       Date:  2021-01-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.